Researchers at Shihezi University School of Medicine have found a new way to slow aggressive prostate cancer. Their work shows gallic acid can break up a molecular chain that helps tumors grow and spread. This chain is called the NF-κB KLF7 L1CAM pathway. The team, led by Professor Jun Zhang, found that gallic acid targets this pathway directly.
Prostate cancer is the second most common cancer in men worldwide. Most patients start with androgen-deprivation therapy. But this treatment often stops working. Tumors become resistant. When that happens, the disease gets harder to control. Doctors need new ways to stop tumor growth and spread. That’s where this research comes in.
Gallic acid is a naturally occurring plant phenolic compound found in tea, wine, berries, and many other foods, and has been studied for its antioxidant, anti-inflammatory, antimicrobial, and anticancer effects.
How gallic acid targets the pathway
The team used RNA sequencing and bioinformatics to look for key drivers in prostate cancer. They found that Krüppel-like factor 7 (KLF7) is a transcription factor that is highly active in these tumors. KLF7 turns on L1 cell adhesion molecule (L1CAM), a protein linked to cancer spread. The researchers also showed that the NF-κB p65 subunit, when phosphorylated, acts as the main switch for this pathway. This switch helps cancer cells become more aggressive.
A recent review by ScienceInsights.org supports this mechanism. NF-κB is a well-known inflammatory pathway. Phosphorylation of the p65 subunit is a key step in turning it on. Using surface plasmon resonance and molecular docking, Zhang’s team showed that gallic acid binds tightly to NF-κB p65. It locks onto the serine 276 phosphorylation site. This stops the pathway from activating KLF7 and L1CAM. The result: cancer cells lose their ability to invade and spread.
Lab and animal results
Tests in the lab gave clear results. Gallic acid slowed down the aggressive behavior of PC-3 and LNCaP prostate cancer cells. It did not harm normal prostate stromal cells. Animal tests backed this up. In mice fed a high-fat diet to induce obesity, gallic acid cut tumor size and weight. Its effect matched that of enzalutamide and bicalutamide, two standard drugs. When used together, the results were even better.
Despite promising preclinical results, no human clinical trials have tested gallic acid as a standalone cancer therapy, and current urology guidelines do not include it as part of standard prostate cancer management.
The study appeared online in the Chinese Medical Journal on July 15, 2026. The data give a strong base for future clinical trials of gallic acid in advanced prostate cancer. The compound looks safe and effective in preclinical models. But there’s a catch. No human trials have tested gallic acid alone for cancer. It is not part of current urology guidelines. The next step is clear. Researchers must see if these lab results hold up in people. For now, gallic acid stands out as a real contender in the search for new prostate cancer treatments.
